WST (STOCKS)
West Pharmaceutical Services, Inc.
$331.430000
+2.610000 (+0.79%)
Prev close: $328.820000
Company Information
- Exchange
- XNYS
- Sector
- Health Technology
- Industry
- Medical Specialties
- CEO
- Eric Mark Green
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $23,415.44M
- Employees
- 10,600
- P/E (TTM)
- 43.96
- P/B (TTM)
- 7.80
- Dividend Yield
- 26.46%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
11
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$2.13 | $1.69 | +0.4365 | +25.78% |
|
Dec 2025 (Q4)
|
$2.04 | $1.85 | +0.1894 | +10.23% |
|
Sep 2025 (Q3)
|
$1.96 | $1.70 | +0.2616 | +15.40% |
|
Jun 2025 (Q2)
|
$1.84 | $1.52 | +0.3153 | +20.68% |
Financial Statements
| Revenues | $3.22B |
| Benefits Costs and Expenses | $2.55B |
| Cost Of Revenue | $2.05B |
| Costs And Expenses | $2.55B |
| Gross Profit | $1.17B |
| Operating Expenses | $513.50M |
| Selling, General, and Administrative Expenses | $405.10M |
| Research and Development | $73.80M |
| Other Operating Expenses | $34.60M |
| Operating Income/Loss | $655.00M |
| Income/Loss Before Equity Method Investments | $670.50M |
| Income/Loss From Continuing Operations After Tax | $533.30M |
| Income/Loss From Continuing Operations Before Tax | $670.50M |
| Income/Loss From Equity Method Investments | $14.40M |
| Income Tax Expense/Benefit | $142.20M |
| Net Income/Loss | $542.70M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $542.70M |
| Net Income/Loss Available To Common Stockholders, Basic | $542.70M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $7.52 |
| Diluted Earnings Per Share | $7.48 |
| Basic Average Shares | 216,400,000 |
| Diluted Average Shares | 217,500,000 |
| Assets | $4.11B |
| Current Assets | $1.83B |
| Inventory | $452.60M |
| Other Current Assets | $1.37B |
| Noncurrent Assets | $2.28B |
| Fixed Assets | $1.70B |
| Intangible Assets | $7.00M |
| Other Non-current Assets | $573.80M |
| Liabilities | $1.12B |
| Current Liabilities | $674.00M |
| Accounts Payable | $252.30M |
| Other Current Liabilities | $421.70M |
| Noncurrent Liabilities | $445.40M |
| Long-term Debt | $202.80M |
| Other Non-current Liabilities | $242.60M |
| Equity | $2.99B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $2.99B |
| Liabilities And Equity | $4.11B |
| Net Cash Flow From Operating Activities | $715.30M |
| Net Cash Flow From Operating Activities, Continuing | $715.30M |
| Net Cash Flow From Investing Activities | -$257.30M |
| Net Cash Flow From Investing Activities, Continuing | -$257.30M |
| Net Cash Flow From Financing Activities | -$346.80M |
| Net Cash Flow From Financing Activities, Continuing | -$346.80M |
| Exchange Gains/Losses | $6.00M |
| Net Cash Flow | $117.20M |
| Net Cash Flow, Continuing | $111.20M |
| Comprehensive Income/Loss | $506.20M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $623.00M |
| Other Comprehensive Income/Loss | $374.40M |
| Other Comprehensive Income/Loss Attributable To Parent | $80.30M |